Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

Simple Summary The breakthrough in developing novel HER2-targeting antibody drug
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …

The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of
HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an …

Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2)
are associated with the development of many tumors. It is currently a crucial treatment for …

Objectives We assessed the interobserver and interantibody reproducibility of HER2
immunohistochemical scoring in an enriched HER2-low–expressing breast cancer cohort …

Abstract In DESTINY-Breast04 (DB-04), safety and efficacy of HER2-targeted antibody-drug
conjugate (ADC) trastuzumab deruxtecan (T-DXd) in previously treated HER2-low …

HER2 (human epidermal growth factor receptor 2) status in breast cancer spans a spectrum
from HER2-positive to ultra-low HER2, each category influencing prognosis and treatment …

Breast cancer is a prevalent malignancy in the present day, particularly affecting women as
one of the most common forms of cancer. A significant portion of patients initially present …

Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of
four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to …

Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast
cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 …